Sage Therapeutics, Inc. (SAGE)
Largest Insider Buys in Sector
SAGE Stock Price History Chart
SAGE Stock Performance
About Sage Therapeutics, Inc.
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive steroid, which is in Phase III clinical trials for treating PPD, major depressive disorders, treatment resistant disorders, generalized anxiety disorders, and bipolar depression; and SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epilepsy and Parkinson's diseases. In addition, its product pipeline comprises SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which has completed Phase I clinical trial for the treatment of depression, Huntington's disease, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. Sage Therapeutics, Inc. has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of zuranolone in Japan, Taiwan, and South Korea; and a collaboration and license agreement with Biogen MA Inc. to jointly develop and commercialize SAGE-217 and SAGE-324 products. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.
Insider Activity of Sage Therapeutics, Inc.
Over the last 12 months, insiders at Sage Therapeutics, Inc. have bought $37,279 and sold $0 worth of Sage Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Sage Therapeutics, Inc. have bought $1.11M and sold $902,026 worth of stock each year.
Highest buying activity among insiders over the last 12 months: Barrett Elizabeth (director) — $37,279.
The last purchase of 2,000 shares for transaction amount of $37,279 was made by Barrett Elizabeth (director) on 2023‑08‑09.
List of Insider Buy and Sell Transactions, Sage Therapeutics, Inc.
| 2023-08-09 | Barrett Elizabeth | director | 2,000 0.0032% | $18.64 | $37,279 | +4.00% | ||
| 2023-05-09 | Barrett Elizabeth | director | 1,000 0.0017% | $50.50 | $50,500 | -58.11% | ||
| 2023-02-10 | Sale | JONAS JEFFREY M | director | 11,643 0.0193% | $44.61 | $519,413 | -41.08% | |
| 2022-11-10 | Greene Barry E | President and CEO | 14,500 0.024% | $34.48 | $500,022 | +19.18% | ||
| 2022-05-05 | Golumbeski George | 8,000 0.0136% | $31.45 | $251,563 | +26.48% | |||
| 2021-08-05 | Greene Barry E | President and CEO | 23,640 0.0401% | $43.15 | $1.02M | -10.58% | ||
| 2021-06-16 | STARR KEVIN P | director | 17,842 0.0311% | $56.05 | $999,983 | -24.87% | ||
| 2021-06-16 | Greene Barry E | President and CEO | 8,800 0.0154% | $56.32 | $495,627 | -24.87% | ||
| 2021-06-16 | FRATES JAMES M | director | 1,810 0.0031% | $55.10 | $99,735 | -24.87% | ||
| 2019-12-09 | Robichaud Albert | Chief Scientific Officer | 25,000 0.0494% | $64.16 | $1.6M | -16.96% | ||
| 2019-12-09 | JONAS JEFFREY M | President & CEO | 7,500 0.0148% | $64.20 | $481,500 | -16.96% | ||
| 2019-08-15 | Sale | FRATES JAMES M | director | 8,000 0.0154% | $160.58 | $1.28M | -58.68% | |
| 2019-05-29 | Sale | JONAS JEFFREY M | President & CEO | 1,075 0.0021% | $170.61 | $183,401 | -20.75% | |
| 2019-05-28 | Sale | JONAS JEFFREY M | President & CEO | 84,661 0.1656% | $174.83 | $14.8M | -20.45% | |
| 2019-05-24 | Sale | JONAS JEFFREY M | President & CEO | 40,356 0.0786% | $175.08 | $7.07M | -20.51% | |
| 2019-05-23 | Sale | JONAS JEFFREY M | President & CEO | 53,908 0.1047% | $174.51 | $9.41M | -20.45% | |
| 2019-05-22 | Sale | Cloonan Michael | Chief Business Officer | 25,000 0.0485% | $175.00 | $4.38M | -20.71% | |
| 2019-05-10 | Sale | Cook Anne Marie | SVP, GC & Secretary | 15,000 0.0293% | $166.14 | $2.49M | -15.12% | |
| 2019-05-06 | Sale | FRATES JAMES M | director | 8,000 0.0148% | $162.22 | $1.3M | -17.11% | |
| 2019-03-21 | Sale | PAUL STEVEN M | director | 7,879 0.0166% | $161.04 | $1.27M | -1.30% |
Insider Historical Profitability
| Barrett Elizabeth | director | 3000 0.005% | $10.84 | 2 | 0 | <0.0001% |
| Third Rock Ventures II, L.P. | 10 percent owner | 3892916 6.4835% | $10.84 | 0 | 1 | |
| STARR KEVIN P | director | 320659 0.534% | $10.84 | 1 | 4 | <0.0001% |
| Robichaud Albert | Chief Scientific Officer | 136400 0.2272% | $10.84 | 2 | 6 | +14.96% |
| PAUL STEVEN M | director | 122400 0.2039% | $10.84 | 1 | 14 | +46.89% |
| JONAS JEFFREY M | director | 121981 0.2032% | $10.84 | 3 | 10 | <0.0001% |
| Greene Barry E | President and CEO | 46940 0.0782% | $10.84 | 3 | 0 | <0.0001% |
| Golumbeski George | 8000 0.0133% | $10.84 | 1 | 0 | +26.48% | |
| FRATES JAMES M | director | 1810 0.003% | $10.84 | 2 | 4 | +11.01% |
| IGUCHI KIMI | CFO & Treasurer | 1413 0.0024% | $10.84 | 2 | 14 | +5.91% |
| Kanes Stephen | Chief Medical Officer | 941 0.0016% | $10.84 | 1 | 10 | +46.89% |
| Cloonan Michael | Chief Business Officer | 461 0.0008% | $10.84 | 0 | 1 | |
| Anderson Thomas | See Remarks | 0 0% | $10.84 | 1 | 3 | +46.89% |
| Cook Anne Marie | SVP, GC & Secretary | 0 0% | $10.84 | 0 | 1 |
Institutional Investor Ownership
| Fidelity Investments | $109.97M | 9.75 | 5.87M | +7.04% | +$7.23M | 0.01 | |
| The Vanguard Group | $107.78M | 9.56 | 5.75M | +8.12% | +$8.1M | <0.01 | |
| RTW Investments, LP | $102.71M | 9.11 | 5.48M | +5.46% | +$5.31M | 1.52 | |
| BlackRock | $91.68M | 8.13 | 4.89M | +4.89% | +$4.28M | <0.01 | |
| Wellington Management Company | $89.06M | 7.9 | 4.75M | -21.61% | -$24.55M | 0.02 | |
| State Street | $84.23M | 7.47 | 4.49M | +14.71% | +$10.8M | <0.01 | |
| Bellevue Group | $83.68M | 7.42 | 4.47M | +27.1% | +$17.84M | 1.28 | |
| Morgan Stanley | $23.55M | 2.09 | 1.26M | +44.33% | +$7.23M | <0.01 | |
| Geode Capital Management | $22.33M | 1.98 | 1.19M | +2.06% | +$451,209.59 | <0.01 | |
| JPMorgan Chase | $21.64M | 1.92 | 1.15M | -30.89% | -$9.67M | <0.01 | |
| Deutsche Bank | $19.31M | 1.71 | 1.03M | +0.27% | +$51,347.60 | 0.01 | |
| Palo Alto Investors Lp | $18.85M | 1.67 | 1.01M | +1.44% | +$267,063.74 | 2.13 | |
| Dimensional Fund Advisors | $17.35M | 1.54 | 925,578 | -4.35% | -$789,085.19 | 0.01 | |
| T. Rowe Price | $15.22M | 1.35 | 811,934 | +69.81% | +$6.26M | <0.01 | |
| Point72 Asset Management | $12.02M | 1.07 | 641,211 | New | +$12.02M | 0.02 | |
| Samlyn Capital, LLC | $11.14M | 0.99 | 594,661 | -22.66% | -$3.27M | 0.2 | |
| Jacobs Levy Equity Management | $10.4M | 0.92 | 555,213 | -25.26% | -$3.52M | 0.05 | |
| Voloridge Investment Management, LLC | $10.36M | 0.92 | 552,641 | +40.73% | +$3M | 0.02 | |
| Northern Trust | $9.86M | 0.88 | 526,333 | -3.01% | -$305,893.04 | <0.01 | |
| Bank of America | $9.83M | 0.87 | 524,595 | +94.62% | +$4.78M | <0.01 | |
| Goldman Sachs | $9.81M | 0.87 | 523,254 | +9.81% | +$876,057.52 | <0.01 | |
| Cowen Group | $8.12M | 0.72 | 433,078 | -67.68% | -$17M | 0.26 | |
| Fisher Asset Management Llc | $8.1M | 0.72 | 432,469 | +0.13% | +$10,194.56 | <0.01 | |
| Baker Bros Advisors LP | $7.63M | 0.68 | 407,217 | New | +$7.63M | 0.1 | |
| Rafferty Asset Management Llc | $7.35M | 0.65 | 392,425 | +27.86% | +$1.6M | 0.02 | |
| Charles Schwab | $7.25M | 0.64 | 387,139 | -6.47% | -$501,594.85 | <0.01 | |
| Hudson Bay Capital Management LP | $7.03M | 0.62 | 375,000 | -5.06% | -$374,800.00 | 0.07 | |
| Ameriprise Financial | $6.74M | 0.6 | 359,535 | +16.45% | +$951,992.01 | <0.01 | |
| Citigroup | $6.31M | 0.56 | 336,473 | +170.56% | +$3.97M | 0.01 | |
| Two Sigma | $6.16M | 0.55 | 328,847 | +32.08% | +$1.5M | 0.01 | |
| Millennium Management LLC | $5.64M | 0.5 | 301,153 | -9.62% | -$600,616.98 | <0.01 | |
| Pinnacle Associates, Ltd. | $5.36M | 0.48 | 285,917 | +69.61% | +$2.2M | 0.09 | |
| Soros Fund Management | $5.15M | 0.46 | 275,000 | New | +$5.15M | 0.21 | |
| American Century Investments | $5.03M | 0.45 | 268,290 | +53.53% | +$1.75M | <0.01 | |
| UBS | $4.78M | 0.42 | 255,226 | +25.6% | +$974,892.23 | <0.01 | |
| Jefferies Financial Group | $4.46M | 0.4 | 238,069 | +84.84% | +$2.05M | 0.08 | |
| Candriam S C A | $4.16M | 0.37 | 222,000 | -2.2% | -$93,700.00 | 0.03 | |
| Jane Street Capital | $3.83M | 0.34 | 204,485 | +196.41% | +$2.54M | <0.01 | |
| 683 Capital Management Llc | $3.75M | 0.33 | 200,000 | New | +$3.75M | 0.42 | |
| Integral Health Asset Management Llc | $3.75M | 0.33 | 200,000 | 0% | +$0 | 0.37 | |
| BNY Mellon | $3.39M | 0.3 | 181,055 | -7.54% | -$276,564.94 | <0.01 | |
| Citadel Advisors LLC | $3.01M | 0.27 | 160,548 | -62.93% | -$5.11M | <0.01 | |
| D. E. Shaw & Co. | $2.99M | 0.27 | 159,338 | -37.43% | -$1.79M | <0.01 | |
| Assenagon Asset Management S.A. | $2.93M | 0.26 | 156,593 | +1,058.4% | +$2.68M | 0.01 | |
| Granahan Investment Management | $2.93M | 0.26 | 156,371 | New | +$2.93M | 0.1 | |
| PDT Partners | $2.69M | 0.24 | 143,390 | -3.63% | -$101,308.46 | 0.2 | |
| Nuveen | $2.67M | 0.24 | 142,694 | 0% | +$0 | <0.01 | |
| Verition Fund Management Llc | $2.63M | 0.23 | 140,449 | +6% | +$148,964.24 | 0.03 | |
| Capital Fund Management | $2.5M | 0.22 | 133,152 | +82.64% | +$1.13M | 0.03 | |
| Levin Easterly Partners Llc | $2.05M | 0.18 | 109,602 | -10.63% | -$244,388.28 | 0.14 |